Medicare Enrolled
Dr. Mark Sonnenschine, D.O.
Hematology & Oncology · Brooklyn, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Sonnenschine from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sonnenschine?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sonnenschine
Dr. Mark Sonnenschine is a hematology & oncology specialist in Brooklyn, NY, with 18 years of NPI registration. Based on federal Medicare data, Dr. Sonnenschine performed 61,652 Medicare services across 879 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sonnenschine received a total of $13,424 from 55 pharmaceutical and/or device companies across 545 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sonnenschine is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 11% volume in NY
$13,424 industry payments
Medicare Practice Summary
Medicare Utilization ↗61,652
Medicare services
Top 11% in NY for hematology & oncology
879
Unique beneficiaries
$3
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,425 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
39,000 | $1 | $2 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
19,601 | $0 | $4 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
925 | $69 | $399 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
860 | $5 | $66 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
289 | $115 | $439 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
231 | $77 | $150 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
215 | $8 | $25 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
209 | $110 | $200 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
152 | $58 | $492 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
122 | $12 | $103 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
48 | $142 | $450 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
63.5% high complexity
33.4% medium
3.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$13,424
Total received (2018-2024)
Avg $1,918/year across 7 years
Top 22% in NY for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
55
Companies
545
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,797 (80.4%)
Other
Charitable contributions, space rental, and other categories
$1,495 (11.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,131 (8.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,999
2023
$2,232
2022
$1,699
2021
$2,119
2020
$2,002
2019
$1,648
2018
$1,725
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Daiichi Sankyo Inc.
$287
Janssen Biotech, Inc.
$253
PFIZER INC.
$216
Novartis Pharmaceuticals Corporation
$206
Merck Sharp & Dohme LLC
$173
Eisai Inc.
$136
TAIHO ONCOLOGY, INC.
$124
Aveo Pharmaceuticals, Inc.
$118
Takeda Pharmaceuticals U.S.A., Inc.
$94
E.R. Squibb & Sons, L.L.C.
$88
Incyte Corporation
$53
Celgene Corporation
$48
Bayer Healthcare Pharmaceuticals Inc.
$37
Mirati Therapeutics, Inc.
$28
Stemline Therapeutics Inc.
$24
Rigel Pharmaceuticals, Inc.
$23
AstraZeneca Pharmaceuticals LP
$20
SOBI, INC
$19
ARRAY BIOPHARMA INC
$18
Agios Pharmaceuticals, Inc.
$18
Alexion Pharmaceuticals, Inc.
$15
Top 3 companies account for 37.8% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$2,199
PFIZER INC.
$1,445
NOVARTIS PHARMACEUTICALS CORPORATION
$1,083
E.R. Squibb & Sons, L.L.C.
$946
Janssen Biotech, Inc.
$933
Incyte Corporation
$880
Daiichi Sankyo Inc.
$581
AstraZeneca Pharmaceuticals LP
$501
Takeda Pharmaceuticals U.S.A., Inc.
$344
Merck Sharp & Dohme LLC
$340
Merck Sharp & Dohme Corporation
$329
Eisai Inc.
$263
Rigel Pharmaceuticals, Inc.
$250
Exelixis Inc.
$247
Celgene Corporation
$235
GENZYME CORPORATION
$229
Genentech USA, Inc.
$215
Amgen Inc.
$186
Lilly USA, LLC
$173
TAIHO ONCOLOGY, INC.
$149
Aveo Pharmaceuticals, Inc.
$118
Janssen Pharmaceuticals, Inc
$113
TESARO, Inc.
$113
Dova Pharmaceuticals
$110
Kite Pharma, Inc.
$105
ARRAY BIOPHARMA INC
$85
SOBI, INC
$83
EISAI INC.
$79
Taiho Oncology, Inc.
$74
Kyowa Kirin, Inc.
$66
Gilead Sciences, Inc.
$64
Alexion Pharmaceuticals, Inc.
$62
Pharmacyclics LLC, An AbbVie Company
$60
Bayer Healthcare Pharmaceuticals Inc.
$60
Seagen Inc.
$59
Shire North American Group Inc
$53
Bayer HealthCare Pharmaceuticals Inc.
$52
Mirati Therapeutics, Inc.
$50
Shield Therapeutics Inc
$48
Stemline Therapeutics Inc.
$43
Puma Biotechnology, Inc.
$42
Regeneron Healthcare Solutions, Inc.
$42
SANOFI-AVENTIS U.S. LLC
$40
G1 Therapeutics, Inc.
$37
Clovis Oncology, Inc.
$36
Ipsen Biopharmaceuticals, Inc
$30
Foundation Medicine, Inc.
$27
Adaptive Biotechnologies Corporation
$21
JAZZ PHARMACEUTICALS INC.
$20
Acceleron Pharma, Inc.
$19
Agios Pharmaceuticals, Inc.
$18
Astellas Pharma US Inc
$18
CTI BioPharma Corp.
$17
Sumitomo Pharma America, Inc.
$17
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$11
Top 3 companies account for 35.2% of all-time payments
Associated products mentioned in payments ›
ACCRUFER · ADCETRIS · AFINITOR · AUGTYRO · Alecensa · Avastin · BOSULIF · BRAFTOVI · CABOMETYX · CALQUENCE · CHANTIX · COSELA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ENHERTU · ERLEADA · Enhertu · Erleada · FASLODEX · FOTIVDA · FOUNDATIONONE · Fabhalta · GAZYVA · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · LifeVest · MEKINIST · MONJUVI · MOVANTIK · MYLOTARG · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Orserdu · PEMAZYRE · POTELIGEO · PROMACTA · PYRUKYND · Pomalyst · REBLOZYL · RETEVMO · RYDAPT · Reblozyl · Rezlidhia · Rubraca · SANCUSO · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SUTENT · Stivarga · TAGRISSO · TECENTRIQ · TECVAYLI · TUKYSA · Tavalisse · Trodelvy · ULTOMIRIS · VELCADE · VERZENIO · VOTRIENT · VPRIV · Vonjo · XALKORI · XARELTO · XOSPATA · XTANDI · ZEJULA · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (80%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
712
Per 100K population
26.9
County median income
$78,548
Nearest hospital
MAIMONIDES MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Sonnenschine is a mixed practice specialist, with above-average Medicare volume (top 11% in NY), with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Sonnenschine experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Sonnenschine performed 39,000 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sonnenschine receive payments from pharmaceutical companies?
Yes. Dr. Sonnenschine received a total of $13,424 from 55 companies across 545 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sonnenschine's costs compare to other hematology & oncology specialists in Brooklyn?
Dr. Sonnenschine's average Medicare payment per service is $3. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sonnenschine) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Brooklyn
Browse hematology & oncology specialists in Brooklyn ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NY
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NY
Which NY hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
NOVARTIS PHARMACEUTICALS CORPORATION Payments to Doctors
See all physicians who received payments from NOVARTIS PHARMACEUTICALS CORPORATION.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology